Noteworthy - Pharmaceutical Executive



EMA Clinical Data Disclosure Plan Under Fire

October 27, 2014

The EMA might have expected that the publication of its plan for proactive release of clinical reports would receive a warm welcome. But, Reflector writes, it is far from a roaring success.

TAG Touts Progress in Global Access to TB Drugs

October 14, 2014

TB advocacy campaigner Treatment Action Group (TAG) has reached a milestone in improving access to TB treatments. Casey McDonald reports.

Unlocking the True Value of Big Data

October 9, 2014

In this special issue of Pharm Exec Global Digest: Unlocking the true value of Big Data; Data privacy and the health sciences; In-silico modeling and real-word outcomes; and more...

How the "Millennials" Demographic is Shaping US Healthcare

October 6, 2014

The US is skewing young again, and the "millennials" have the clout to color everything from the nation's cultural landscape to the conduct of business practices like marketing and customer engagement, writes Bill Looney.

IDEAlogue for Innovation: A Conversation with Italy's Fabio Pammolli

October 6, 2014

Fabio Pammolli, selected by the European Commission to author a set of critical overviews on the pharma sector, talks about the need for a dramatic change in industrial strategy.

Big Data Meets Personalized Medicine

October 2, 2014

Data analytic strategies can help companies capitalise on personalised medicine, writes Jill E. Sackman and Michael Kuchenreuther.

Italy's AIFA: Agenda for Regulatory Leadership

October 2, 2014

Pharm Exec talks with Dr. Sergio Pecorelli, Chairman of the Italian Medicines Agency (AIFA), an organization respected in global regulatory circles for its precedent-setting work on advanced cost-effectiveness metrics.

New Patent-Defense Path for Pharma

October 1, 2014

Inter Partes Review can potentially offer a more economical and streamlined litigation strategy for pharma and biotech players, writes David Dalke.

The Gate Keeper: Dr. David Haslam, Chair of NICE, UK

October 1, 2014

NICE's David Haslam discusses the UK drug watchdog's new challenge in meeting expectations around what quantitative calculations of value mean to patient access today.


Click here